Nasdaq-listed Leap Therapeutics buys an additional $18M in ZEC

Nasdaq-listed Leap Therapeutics (LPTX) has purchased an additional 29,869 ZEC for $18 million at an average price of $602.63, PR Newswire reported. The acquisition brings the company's total holdings to 232,644 ZEC.